Dr Sudarshini Ramanathan is a neurologist and early career clinician-scientist with a subspecialty interest in neuroimmunology. She is focused on clinical and laboratory research related to antibody-mediated neurological disorders, including demyelination and autoimmune encephalitis; as well as the management of patients with multiple sclerosis. She is a clinical neuroimmunologist affiliated with the Department of Neurology at Westmead Hospital, a Senior Lecturer at the University of Sydney, and a postdoctoral research fellow at the Kids Neuroscience Centre at the Children’s Hospital at Westmead. Dr Ramanathan completed her PhD on the clinical, radiological, and immunological characterisation of patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination. In 2016 she established and is now the lead investigator of the Australian and New Zealand MOG Study Group. This is a unique collaborative platform of over 100 adult and paediatric neurologists from over 40 tertiary, metropolitan, rural, and remote centres throughout Australasia, with the goal of better understanding antibody-associated demyelination. This has led to a number of publications which elaborate on the phenotype and management of these patients.
She has been recently awarded an NHMRC Neil Hamilton Fairley Early Career Fellowship and is currently undertaking a postdoctoral fellowship in Oxford with the Autoimmune Neurology Group at the John Radcliffe Hospital and the University of Oxford for 2 years, before returning to Sydney. Her research in Oxford involves exploring antigenic targets in seronegative patients with suspected antibody-associated demyelination, and mechanisms of disease pathogenesis and treatment responses in subgroups of patients with antibody-associated demyelination and autoimmune encephalitis.
Dr Ramanathan is committed to translational research from basic science projects which help us better understand underlying mechanisms of disease pathogenesis, to clinical projects which enable us to diagnose patients at an earlier stage in their clinical course, and treat patients with neuroimmunological disorders effectively, in order to minimise disability and improve outcomes.